Author

Frank Hoentjen

COLORECTAL CANCER RISK IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH HIGH-GRADE DYSPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
COLORECTAL CANCER RISK IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH HIGH-GRADE DYSPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Frank Hoentjen  et al.

POSTOPERATIVE PROPHYLACTIC THIOPURINES OR BIOLOGICALS ARE PROTECTIVE FOR CLINICAL AND ENDOSCOPIC RECURRENCE AT SHORT TERM FOLLOW-UP AFTER PRIMARY ILEOCECAL RESECTION IN CROHN'S DISEASE, BUT NOT ASSOCIATED WITH A LONG-TERM BENEFICIAL EFFECT ON THE RISK OF
POSTOPERATIVE PROPHYLACTIC THIOPURINES OR BIOLOGICALS ARE PROTECTIVE FOR CLINICAL AND ENDOSCOPIC RECURRENCE AT SHORT TERM FOLLOW-UP AFTER PRIMARY ILEOCECAL RESECTION IN CROHN'S DISEASE, BUT NOT ASSOCIATED WITH A LONG-TERM BENEFICIAL EFFECT ON THE RISK OF

Frank Hoentjen  et al.

USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE
USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE

Frank Hoentjen  et al.

TIME TRENDS FOR POSTOPERATIVE RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN'S DISEASE: DETAILED EVALUATION OF ASSOCIATED FACTORS
TIME TRENDS FOR POSTOPERATIVE RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN'S DISEASE: DETAILED EVALUATION OF ASSOCIATED FACTORS

Frank Hoentjen  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Frank Hoentjen  et al.

SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP
SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP

Frank Hoentjen  et al.

RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)
RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)

Frank Hoentjen  et al.

LOSS OF RESPONSE AND DOSE ESCALATION OF INFLIXIMAB AND ADALIMUMAB IN ULCERATIVE COLITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
LOSS OF RESPONSE AND DOSE ESCALATION OF INFLIXIMAB AND ADALIMUMAB IN ULCERATIVE COLITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Frank Hoentjen  et al.

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Frank Hoentjen  et al.

REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ON WORK IMPAIRMENT AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS
REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ON WORK IMPAIRMENT AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS

Frank Hoentjen  et al.

SAFETY OF REDUCED CLINICAL MONITORING IN PATIENTS WITH STABLE INFLAMMATORY BOWEL DISEASE ON MAINTENANCE THIOPURINE THERAPY
SAFETY OF REDUCED CLINICAL MONITORING IN PATIENTS WITH STABLE INFLAMMATORY BOWEL DISEASE ON MAINTENANCE THIOPURINE THERAPY

Frank Hoentjen  et al.

DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION
DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION

Frank Hoentjen  et al.

PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?
PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?

Frank Hoentjen  et al.

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Frank Hoentjen  et al.

PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY
PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY

Frank Hoentjen  et al.

WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY
WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY

Frank Hoentjen  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Frank Hoentjen  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

Frank Hoentjen  et al.

Item 1 - 18 / 18
1